CD19 and B-cell chronic lymphocytic leukemia: Outcomes in 42 CLL patients randomized to receive low (5 × 107 cells/kg) vs. high-dose (5 × 108 cells/kg) CD19 CAR T-cells[8] demonstrated CR and ORR of 28% and 44% at 4 weeks, respectively.